Ultragenyx Pharmaceutical (RARE) Other financing activities (2020 - 2024)
Ultragenyx Pharmaceutical (RARE) reported Other financing activities of $7.0 million for Q3 2024, up 580.93% quarter-over-quarter from $1.0 million in Q4 2023.
Ultragenyx Pharmaceutical (RARE) Other financing activities (2020 - 2024) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has 5 years of Other financing activities data on file, last reported at $7.0 million in Q3 2024.
- Other financing activities for Q3 2024 came in at $7.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $7.0 million (changed 0.0% YoY), and the FY2024 annual result was $7.0 million, up 600.0% from the prior year.
- Other financing activities improved to $7.0 million in Q3 2024 per RARE's latest filing, from $1.0 million in the prior quarter.
- Over five years, Other financing activities peaked at $7.0 million in Q3 2024 and troughed at -$147000.0 in Q3 2022.
- A 5-year average of $419812.5 and a median of -$99500.0 in 2020 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2021 and 2023: Other financing activities slumped 239.39% in 2021, then jumped 963.87% in 2023.
- A 5-year view of Other financing activities shows it stood at -$87000.0 in 2020, then plunged by 63.22% to -$142000.0 in 2021, then climbed by 16.2% to -$119000.0 in 2022, then jumped by 963.87% to $1.0 million in 2023, then soared by 580.93% to $7.0 million in 2024.
- Business Quant data shows RARE's Other financing activities at $7.0 million in Q3 2024, $1.0 million in Q4 2023, and -$56000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ultragenyx Pharmaceutical | 2.77 Bn | 2.36 Bn | 106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 7.00 Mn |
| Sep 30, 2024 | 7.00 Mn |
| Dec 31, 2023 | 1.03 Mn |
| Dec 31, 2023 | 1.03 Mn |
| Jun 30, 2023 | -56,000.00 |
| Jun 30, 2023 | -56,000.00 |
| Mar 31, 2023 | 28,000.00 |
| Mar 31, 2023 | 28,000.00 |
| Dec 31, 2022 | -119,000.00 |
| Dec 31, 2022 | -119,000.00 |
| Sep 30, 2022 | -147,000.00 |
| Sep 30, 2022 | -147,000.00 |
| Jun 30, 2022 | -146,000.00 |
| Jun 30, 2022 | -146,000.00 |
| Mar 31, 2022 | -143,000.00 |
| Mar 31, 2022 | -143,000.00 |
| Dec 31, 2021 | -142,000.00 |
| Dec 31, 2021 | -142,000.00 |
| Sep 30, 2021 | -124,000.00 |
| Sep 30, 2021 | -124,000.00 |